Navigation Links
IRIDEX Announces Shipment of New IQ 577(TM) Laser Systems
Date:4/30/2009

New Technology Represents First True Yellow Laser with CW-Pulse(TM) and MicroPulse(TM) Delivery

MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- IRIDEX Corporation, (Nasdaq: IRIX) today announced the commencement of shipments to customers of the IQ 577 laser systems. The IQ 577 is a high-power, true yellow (577 nm wavelength) laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma.

The IQ 577 offers tangible benefits to both patient and physician. Patients benefit from less discomfort. The higher inherent absorption in blood, together with the lower scattering of the 577 nm yellow laser wavelength, compared with 532 nm green laser systems, helps to reduce the therapeutic power requirements and resultant patient discomfort. Physicians benefit from efficiencies due to its easy to understand user interface, wireless foot pedal control with power adjust capability, and audible confirmation of adjustments.

"The 577 nm laser wavelength previously was available to ophthalmologists only in argon-pumped dye laser systems," commented Theodore A. Boutacoff, President and CEO. "These argon-pumped dye laser systems, now obsolete, were popular at one time; however, they were large, had high electrical power demands, required circulating water for cooling, and were expensive to maintain and service. In contrast, we have directed our company's experience and expertise to develop the IQ 577, reintroducing this laser wavelength to clinicians in a modern product utilizing reliable and efficient solid-state laser technology. The integration of MicroPulse technology into the IQ 577 ensures that it will satisfy not only today's clinical requirements, but also those of the future. Also in contrast
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results
2. IRIDEX Announces Fourth Quarter and Full Year 2008 Conference Call and Release Date
3. IRIDEX Reports Third Quarter 2008 Financial Results
4. IRIDEX Announces Third Quarter 2008 Conference Call and Release Date
5. IRIDEX Reports First Quarter 2008 Financial Results
6. IRIDEX Announces First Quarter 2008 Conference Call and Release Date
7. IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results
8. IRIDEX Announces Fourth Quarter and Full Year 2007 Conference Call and Release Date
9. IRIDEX Reports Third Quarter Financial Results
10. IRIDEX Announces Third Quarter 2007 Conference Call and Release Date
11. Theodore A. Boutacoff Appointed President & CEO of IRIDEX

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...minutes of hospital arrival, study finds , ...nwide program to get faster treatment for people w...tically reduced the time between hospital arrival ...uarters of people with STEMI heart attacks -- so c...t shows major blockage of a heart artery -- were r...
(Date:12/2/2009)...c syndrome, study finds , , WEDNESDAY, D...ugh to keep overweight college football players fr...at can lead to heart disease, a new study suggests...olleges and found that two-thirds were obese. Of t...f conditions that raise the risk for heart disease...
(Date:12/2/2009)...swire-USNewswire/ -- Huntington Memorial Hospital,...roval from the Joint Commission, designating the h...ngton will join the network of "approved stroke ce..., "This is a significant milestone for the hosp...Pasadena and its surrounding communities," said Ar...
(Date:12/2/2009)...RNewswire-USNewswire/ -- Researchers from around t...er research at the annual American Society of Hema...8, 2009. ,, Throughout the ASH conference, The...cluding Chief Medical Officer Barton Kamen, M.D., ...ildy Dillon, and Vice President, Research Communic...
(Date:12/2/2009)... Care Support of America,s model ...ced Illness Coordinated Care (AICC) , has been sho... life as well as improve the quality of life for s...ing mortality. These are the principal findings of...aged Care (November 2009). ,, Based on a r...
Breaking Medicine News(10 mins):Health News:Heart Attack Treatment Speeds Up Nationwide 2Health News:Heart Attack Treatment Speeds Up Nationwide 3Health News:Oversized College Football Players May Face Heart Risks 2Health News:Huntington Hospital Earns Designation as Primary Stroke Center 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 4
..., BOSTON, Feb. 11 Innerscope Research(TM), a revo... today the appointment of Dr. Caleb Siefert as Sen...alyses and study designs in the emerging field of ...erscope continue to develop and organize a large-s...
..., WASHINGTON, Feb. 11 Teva Pharmaceuticals USA, t...nnounced that it was launching a nationwide campai...gram, called the "Year of Affordable Healthcare" c...ars of savings. , , "With a new administration an...
..., WASHINGTON, Feb. 11 Hospice Foundation of Ameri...t grants program. Grants have been awarded to five...adolescents. Priority was given to organizations t... offer support to programs that are doing such vit...
..., Growing up with a heroin-addicted parent expos...s before the age of 18 and new research indicates ... in overcoming such adverse events., In addition... and having a parent die, and the study found 70 p...
..., DES MOINES, Iowa, Feb. 11 Protocol Driven Hea...s Steps online action plans with two additions: di...tegral components of the ConXus health-improvement...ibrary, each new action plan comprises: , , , ...
..., ATLANTA, Feb. 11 Sensiotec Inc. announces F... ultra-wideband (UWB) non-contact,continuous monit...and,movement. Under the brand name Preventa(TM), S... 2000 received the sign off from,the FDA,s Divisio...
Other Medicine News:Health News:Innerscope Research(TM) Names Caleb Siefert as Senior Scientist to Lead Company's Statistical Analyses and Study Designs 2Health News:Teva Launches National Advocacy Campaign for Affordable Healthcare 2Health News:Hospice Foundation of America Awards $25,000 to Support Grieving Children and Adolescents 2Health News:Girls growing up with heroin-addicted parent more resilient than boys 2Health News:PDHI Adds Diabetes and Heart Disease Prevention to ConXus Steps Library of Action Plans 2Health News:PDHI Adds Diabetes and Heart Disease Prevention to ConXus Steps Library of Action Plans 3Health News:Sensiotec Announces FDA 510(k) Class II Clearance for the World's First UWB Healthcare Unbound, Wireless, Non-Contact, Vital Signs and Movement Monitor 2
(Date:12/1/2009)...EACH, Calif., Dec. 1 Reproductive ...ive Single Embryo Transfer (eSET) Encouragement Pr...s with good embryo quality and a good prognosis fo... by transferring a single embryo. ,, The bigges...is reducing the number of multiple pregnancies, ev...
(Date:12/1/2009)...AN, N.J., Dec. 1 Johnson & Joh...L.C. announced today that it has submitted a New D...ministration (FDA) for tapentadol extended release...or the management of moderate to severe chronic pa...ronic pain, defined as pain that persists for long...
(Date:12/1/2009)...W YORK, Dec. 1 Reportlinker.com an...able in its catalogue: ,, Molecular Diagnostic...tlinker.com/p0164231/Molecular-Diagnostics---A-Wor... market is being driven by several growth factors ...ndle techniques, which combine optimized sample pr...
Breaking Medicine Technology:Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 2New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 3New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 4New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 5New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 6New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain 7Reportlinker Adds Molecular Diagnostics - A World Market Review 2Reportlinker Adds Molecular Diagnostics - A World Market Review 3Reportlinker Adds Molecular Diagnostics - A World Market Review 4Reportlinker Adds Molecular Diagnostics - A World Market Review 5Reportlinker Adds Molecular Diagnostics - A World Market Review 6Reportlinker Adds Molecular Diagnostics - A World Market Review 7Data on WaferGens SmartChip 28TM 29 System to be Presented at 3rd Annual Rediscovering Biomarkers Conference 12908 1Data on WaferGens SmartChip 28TM 29 System to be Presented at 3rd Annual Rediscovering Biomarkers Conference 12908 2Data on WaferGens SmartChip 28TM 29 System to be Presented at 3rd Annual Rediscovering Biomarkers Conference 12908 3Data on WaferGens SmartChip 28TM 29 System to be Presented at 3rd Annual Rediscovering Biomarkers Conference 12908 4Parents Guide to Cord Blood Foundation Introduces New Brochure During Cord Blood Awareness Month to Address Critical Education Gap 50861 1Parents Guide to Cord Blood Foundation Introduces New Brochure During Cord Blood Awareness Month to Address Critical Education Gap 50861 2Parents Guide to Cord Blood Foundation Introduces New Brochure During Cord Blood Awareness Month to Address Critical Education Gap 50861 3CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter 50857 1CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter 50857 2
...RVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - Reat...tation of new,preclinical data showing their lead ...402, is effective at protecting against,common tox...his,data was presented at the annual meeting of th...Cancer (MASSC) in St Gallen,Switzerland., Reata s...
...CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- A...nced that it will host a,conference call and live ...to discuss data from Trial CL-06, the first of two...s the safety and,effectiveness of cethromycin, a n...ommunity acquired pneumonia (CAP). , Conference Ca...
Other Medicine Technology:RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 2RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 3Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials 2
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
Medicine Products: